Intravenous Atropine in Reducing Reperfusion Arrhythmias, Conduction Abnormalities and Hypotension in Inferior ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

March 9, 2026 updated by: Ain Shams University
People with acute inferior wall myocardial infarction will be given an intravenous drug called atropine that increases the heart rate to check if it prevents heart rhythm disturbances during performing coronary intervention

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

158

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Abbasia
      • Cairo, Abbasia, Egypt
        • Ain Shams University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Acute inferior ST elevation myocardial infarction

Exclusion Criteria:

  • Execution of rescur percutaneous coronary intervention after thrombolysis
  • Mechanical complications or no reflow or spontaneous reperfusion.
  • Prior implantation of permanent or temporary pacemakers
  • History of bradycardia, hypotension or ventricular tachycardia with a definitive cause (unrelated to the disease under study)
  • Prior coronary artery bypass graft surgery
  • Atropine contraindications Unwillingness to participate in the

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Atropine arm
This group will receive intravenous atropine 1 mg immediately before wire crossing
Drug: Intravenous atropine immediately before wire crossing during primary percutaneous coronary intervention
Intravenous atropine 1 mg immediately before wire crossing during primary percutaneous coronary intervention
Placebo Comparator: Placebo arm
This group will receive intravenous normal saline immediately before wire crossing
Drug: Intravenous normal saline as placebo immediately before wire crossing during primary percutaneous coronary intervention
Intravenous normal saline as placebo immediately before wire crossing during primary percutaneous coronary intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Conduction abnormalities
Time Frame: Periprocedurally
Occurrence of conduction abnormalities
Periprocedurally
Reperfusion arrhythmias
Time Frame: Periprocedurally
Occurrence of reperfusion arrhythmias
Periprocedurally

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Major adverse cardiac events
Time Frame: Periprocedurally
Inhospital major adverse cardiac events including all-cause mortality, cardiovascular mortality, stroke and myocardial infarction
Periprocedurally

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ain Shams University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2025

Primary Completion (Actual)

February 28, 2026

Study Completion (Actual)

February 28, 2026

Study Registration Dates

First Submitted

November 1, 2025

First Submitted That Met QC Criteria

December 4, 2025

First Posted (Actual)

December 8, 2025

Study Record Updates

Last Update Posted (Actual)

March 10, 2026

Last Update Submitted That Met QC Criteria

March 9, 2026

Last Verified

October 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FMASU R49/2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myocardial Infarction

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe